Ocugen, Inc. — Director's Dealing 2015

Feb 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2015-02-02

Reporting Person: GILL DAVID N (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-02-02	Employee Stock Option (Right to Buy)	$8.30	A	13200	Acquired	2025-01-02	Common Stock (13200)	Direct

Footnotes

F1: Exercisable with respect to 25% of the shares after 12 months of continuous service with the Issuer, with the balance becoming exercisable in equal quarterly installments over the next 36 months of continuous service thereafter.